{
    "paper_id": "PMC7192108",
    "metadata": {
        "title": "The Dermatologist\u2019s Perspective: Why is COVID-19 mortality lower in females than males?",
        "authors": [
            {
                "first": "Dedee",
                "middle": [
                    "F."
                ],
                "last": "Murrell",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Jenny",
                "middle": [
                    "E."
                ],
                "last": "Murase",
                "suffix": "",
                "email": null,
                "affiliation": {}
            }
        ]
    },
    "body_text": [
        {
            "text": "The current COVID-19 pandemic is upon us, and factors that are contributing to the mortality in apparently healthy people are yet not understood. The epidemiologic statistics from the source at Wuhan and death rates in Iran, Italy and Spain reveal almost double mortality in men over women. (1,2, 3)",
            "cite_spans": [],
            "section": "Introduction",
            "ref_spans": []
        },
        {
            "text": "Some of these excess deaths are attributed to the increased prevalence of smoking amongst men in China and the attendant co-morbidities associated with chronic smoking, but in the European Union many women smoke as well, yet the mortality is still much higher in men. (1) Could estrogen have a role?",
            "cite_spans": [],
            "section": "Introduction",
            "ref_spans": []
        },
        {
            "text": "We know that the COVID-19 virus uses its spike protein to gain entry to cells, via the Angiotensin Converting Enzyme-2 (ACE-2) protein, a receptor for the virus which is expressed on a number of tissues in humans, including the mucosal linings of the heart, kidneys lungs, oral cavity and eyes. (4)",
            "cite_spans": [],
            "section": "Introduction",
            "ref_spans": []
        },
        {
            "text": "The expression of ACE-2 is reduced by estrogen, whilst it is increased by testosterone. (5,6,7) Hence, females, who have much lower levels of testosterone than males, would receive a lower total viral load on infection, unless they were post-menopausal on no estrogen replacement therapy.",
            "cite_spans": [],
            "section": "Introduction",
            "ref_spans": []
        },
        {
            "text": "ACE-2 levels are low in newborns and increase with age, which is another factor that may protect the young from COVID-19. (8)",
            "cite_spans": [],
            "section": "Introduction",
            "ref_spans": []
        },
        {
            "text": "Ibuprofen and potentially other nonsteroidal anti-inflammatory drugs (NSAIDs) increase the levels of ACE2 and may be taken by women when they have headaches or menstrual cramps or by men with sporting injuries. These may explain some of the younger patients who become vulnerable as these are sold \u2018over the counter,\u2019 and this information may not be available to doctors when sick patients arrive to the hospital.",
            "cite_spans": [],
            "section": "Introduction",
            "ref_spans": []
        },
        {
            "text": "ACE inhibitors and Angiotensin II Receptor Blockers (ARBs) taken for hypertension and a variety of other cardiac and renal indications also increase ACE2 expression by a feedback loop. Recently published guidelines from various professional societies state that there is insufficient evidence to cease such medications in this pandemic. Nevertheless, large Randomized Controlled Trials (RCTs) have previously found no outcome difference in complications of these drugs and calcium channel blockers in terms of strokes and cardiac deaths. (9) Hence, for the period of the pandemic would it not be worth considering this on a case by case basis depending on the patients\u2019 other risk factors, including male sex, smoking, immunosuppression and other co-morbidities? Many of our severe psoriasis patients have all the aforementioned co-morbidities and are taking these medications for their hypertension.",
            "cite_spans": [],
            "section": "Introduction",
            "ref_spans": []
        },
        {
            "text": "Behavioural aspects could also reduce the survival in males, as women are more likely to seek medical attention early in the course of an illness than males. (10f)",
            "cite_spans": [],
            "section": "Introduction",
            "ref_spans": []
        },
        {
            "text": "What advice can we glean from the above facts which may assist the population at large?1.Men should consider reducing consumption of androgenic steroid supplements. Many protein powders taken by young men and older men contain dihydroepiandrosterone (DHEA), an androgenic steroid, and potentially other androgens.2.Post-menopausal women and women taking progestin-only contraceptives may wish to speak to their treating physicians about temporarily using estrogen containing alternatives, if there are no contraindications.3.Transgender individuals may wish to reduce testosterone supplements or take testosterone blockers, depending on the situation, to reduce testosterone exposure.4.Avoid taking ibuprofen and other NSAIDs if possible, and take acetaminophen for pain instead.5.If taking ACE inhibitors or ARBs for hypertension, consider switching to another agent during the pandemic.\n",
            "cite_spans": [],
            "section": "Introduction",
            "ref_spans": []
        },
        {
            "text": "\nGuan et al., 2020, JingLi et al., 2019, Shi et al., 2020, Harmer et al., 2002, White, 2019, Zapater P1, Novalbos J, Gallego-Sand\u00edn S, Hern\u00e1ndez FT, , 2004 May, Komukai and Mochizuki, 2010 Dec, Dalpiaz et al., 2015, Turnbull F1; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet, 2003, Wang et al., 2013.",
            "cite_spans": [
                {
                    "start": 1,
                    "end": 18,
                    "mention": "Guan et al., 2020",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 20,
                    "end": 39,
                    "mention": "JingLi et al., 2019",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 41,
                    "end": 57,
                    "mention": "Shi et al., 2020",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 59,
                    "end": 78,
                    "mention": "Harmer et al., 2002",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 80,
                    "end": 91,
                    "mention": "White, 2019",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 93,
                    "end": 159,
                    "mention": "Zapater P1, Novalbos J, Gallego-Sand\u00edn S, Hern\u00e1ndez FT, , 2004 May",
                    "ref_id": "BIBREF5"
                },
                {
                    "start": 161,
                    "end": 192,
                    "mention": "Komukai and Mochizuki, 2010 Dec",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 194,
                    "end": 214,
                    "mention": "Dalpiaz et al., 2015",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 216,
                    "end": 453,
                    "mention": "Turnbull F1; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet, 2003",
                    "ref_id": "BIBREF8"
                },
                {
                    "start": 455,
                    "end": 472,
                    "mention": "Wang et al., 2013",
                    "ref_id": "BIBREF9"
                }
            ],
            "section": "Uncited references",
            "ref_spans": []
        }
    ],
    "ref_entries": {},
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "",
            "authors": [],
            "year": 2020,
            "venue": "N Engl J Med",
            "volume": "382",
            "issn": "18",
            "pages": "1708-1720",
            "other_ids": {
                "DOI": [
                    "10.1056/NEJMoa2002032"
                ]
            }
        },
        "BIBREF1": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF2": {
            "title": "Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan",
            "authors": [
                {
                    "first": "Y.",
                    "middle": [],
                    "last": "Shi",
                    "suffix": ""
                },
                {
                    "first": "X.",
                    "middle": [],
                    "last": "Yu",
                    "suffix": ""
                },
                {
                    "first": "H.",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": "H.",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "R.",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Sheng",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Critical Care",
            "volume": "24",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF3": {
            "title": "Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme",
            "authors": [
                {
                    "first": "D.",
                    "middle": [],
                    "last": "Harmer",
                    "suffix": ""
                },
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Gilbert",
                    "suffix": ""
                },
                {
                    "first": "R.",
                    "middle": [],
                    "last": "Borman",
                    "suffix": ""
                },
                {
                    "first": "K.L.",
                    "middle": [],
                    "last": "Clark",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "FEBS Lett.",
            "volume": "532",
            "issn": "",
            "pages": "107-110",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF4": {
            "title": "Fleeman R Arnold A: Sex differences in metabolic effects of the renin angiotensin system",
            "authors": [
                {
                    "first": "M.C.",
                    "middle": [],
                    "last": "White",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Biology of Sex Differences",
            "volume": "10",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1186/s13293-019-0247-5"
                ]
            }
        },
        "BIBREF5": {
            "title": "Abad-Santos F. Gender differences in angiotensin-converting enzyme (ACE) activity and inhibition by enalaprilat in healthy volunteers",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Zapater P1, Novalbos J, Gallego-Sand\u00edn S, Hern\u00e1ndez FT,",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "J Cardiovasc Pharmacol.",
            "volume": "43",
            "issn": "5",
            "pages": "737-744",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF6": {
            "title": "Gender and the renin-angiotensin-aldosterone system",
            "authors": [
                {
                    "first": "K.",
                    "middle": [],
                    "last": "Komukai",
                    "suffix": ""
                },
                {
                    "first": "S.",
                    "middle": [],
                    "last": "Mochizuki",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Fundam Clin Pharmacol.",
            "volume": "24",
            "issn": "6",
            "pages": "687-698",
            "other_ids": {
                "DOI": [
                    "10.1111/j.1472-8206.2010.00854.x"
                ]
            }
        },
        "BIBREF7": {
            "title": "Sex Hormones Promote Opposite Effects on ACE and ACE2 Activity, Hypertrophy and Cardiac Contractility in Spontaneously Hypertensive Rats",
            "authors": [
                {
                    "first": "P.L.M.",
                    "middle": [],
                    "last": "Dalpiaz",
                    "suffix": ""
                },
                {
                    "first": "Lamas",
                    "middle": [
                        "AX"
                    ],
                    "last": "Caliman",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "IF,",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "PLOS",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1371/journal.pone.0127515"
                ]
            }
        },
        "BIBREF8": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF9": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        }
    }
}